Abstract: P-glycoprotein (P-gp), as the most important efflux transporter in intestines, plays the key role to determine the bioavailability of many drugs. The three-dimensional (3D) organoid model is suitable to imitate small intestinal epithelium. In this study, a rapid, sensitive and efficient method to measure rhodamine 123 (Rh123, P-gp substrate) in 3D organoids was developed to analyse P-gp-mediated drug transport. Ultrasonic cell disruptor was used to smash the organoid, and automatic microplate reader was used for detecting the concentration of Rh123 (k ex /k em = 485/520 nm). Moreover, verapamil, quinidine and mitotane were used to make validation about this newly developed approach. All three P-gp inhibitors significantly inhibited the transport of Rh123 into 3D organoids. Therefore, the above-mentioned method could serve as a new model for P-gp inhibitor screening in a high-throughput way.
A variety of drugs currently used in clinical practice are subject to active efflux from cells by drug-transporting proteins, of which P-glycoprotein (P-gp; ABCB1) is one of the most important [1, 2] . P-gp, belonging to the family of ATP-binding cassette (ABC) transporters, is localized at the apical side of the cell membrane in tissues involved in absorption, distribution and excretion, such as the intestine, heart and kidney [3] [4] [5] [6] . Therefore, P-gp plays an important role in determining the bioavailability of drugs, especially the orally administered drugs [7] [8] [9] [10] . In addition, P-gp is also overexpressed in tumour cells, which is one major reason for the generation of multi-drug resistance (MDR) in chemotherapy [10] [11] [12] . Hence, drugs interacted with P-gp may probably affect the P-gpmediated drug transport.
Until now, various in vitro models have been reported to imitate the intestinal epithelium for drug transport study. In particular, caco-2 cell monolayer model is the most commonly used for the high-throughput screening of drug permeability and identification of substrates and inhibitors of P-gp [13, 14] . Recently, the culture condition to build crypt-villus structures (organoids) from single intestinal epithelium stem cells has been developed [15] . When cultured in Matrigel with advanced DMEM/F12 medium (containing important growth factors), single intestinal crypt will undergo multiple crypt fission events and form the enclosed three-dimensional structure. Compared with caco-2 cells, the organoids are more similar to intestinal epithelium both physiologically and morphologically. Thus, the organoids are also used to study P-gp-mediated drug transport via the measurement of rhodamine 123 (Rh123) [16] . Although the current method is able to visualize Rh123 performed with the real-time imaging system [16] , there are several shortcomings in it, such as long detection cycle, which is the restraining factor for high-throughput drug screening. Therefore, the aim of this study was to develop a rapid, sensitive and efficient method to measure Rh123 in 3D organoids. At the same time, the developed assay in the organoid model could serve as a new model for P-gp inhibitors screening in a high-throughput way. Advanced DMEM/F12 medium and m-EGF were purchased from Invitrogen (Carlsbad, CA, USA). R-spondin1 and m-noggin were bought from Pepro Tech Inc. (Rocky Hill, NJ, USA). Trizol Reagent was bought from Zhiyuan (Yong'an, China). Prime Script RT Reagent Kit was purchased from Takara (Dalian, China). Primary antibody for P-gp was purchased from Abcam (Cambridge, UK). The anti-rabbit antibody, DAB kit and streptavidin-peroxidase complex were purchased from Neobioscience Co. (Shenzhen, China).
Materials and Methods
Animals. C57BL/6 mice were bought from National Rodent Laboratory Animal Resources, Shanghai Branch of China. All the studies in animals were approved by the Ethics Committee on Animal Experimentation of the East China Normal University (Shanghai, China).
Organoid culture. Culture of organoid was performed according to previous procedure [15] . Crypts were released from C57BL/6 mice small intestine by incubating in PBS containing 2 mM EDTA. After counted, they were mixed with Matrigel at 10,000 crypts/mL and 5 lL of Matrigel was seeded in 96-well plates. Then, 100 lL of advanced DMEM/F12 medium containing growth factors (50 ng/mL m-EGF, 500 ng/mL R-spondin1 and 100 ng/mL Noggin) was added. The medium was changed every 2 days.
Morphological structure observation. On the fourth cultured day, the morphological structure of organoids was observed on a microscope IX 71 (Olympus, Tokyo, Japan) and images of organoids were acquired on an Olympus DP 71 photographic system.
Reverse-transcription PCR. After isolated from the Matrigel, total RNA of organoids was extracted with Trizol according to the instruction of the manufacturer. The RNA was reverse-transcribed into cDNA by Takara RR036A RT-kit according to the commercial construction. The extraction of RNA in crypt and intestine was same as that in organoids. To detect the expression of P-gp mRNA, selective primers were designed and synthesized as follows: sense (S): Immunohistochemistry. The organoids and intestine were fixed in 4% paraformaldehyde and dehydrated with gradient ethanol. Followed by paraffin embedding, 4-lm-thick sections were taken. Paraffin sections were stained using a three-step immunoperoxidase (sandwich) technique [17] . Primary antibody was a rabbit anti-MDR1 monoclonal antibody, the secondary antibody was a goat anti-rabbit antibody, and the third antibody was a streptavidin-peroxidase complex. The detection for both reactions was conducted with diaminobenzidine (DAB Kit, Neobioscience Co., Shenzhen, China). Sections were viewed with a microscope (LEICA DM4000 B LED, Wetzlar, Germany).
Measurement of Rh123 in organoids.
Three-dimensional organoids were counted on the third cultured day before incubating with Rh123, the substrate of P-gp. The concentration of Rh123 was 10 lM according to the previous studies [18, 19] . The studies were divided into four groups, including control (Rh123 alone), averapamil, quinidine and mitotane together with Rh123, respectively. The concentration of P-gp inhibitors was 20 lM. After incubated with drugs for 20, 40, 60, 80 and 100 min. and washed twice with 150 lL of PBS, the organoids were gathered in PBS and broken with ultrasonic cell disruptor. The homogenate was centrifuged at 12,000 9 g for 5 min. at 4°C, and the supernatant was collected to determine the fluorescence intensity (k ex /k em = 485/520 nm) by automatic microplate reader (FLUOStar OPTIMA) (BMG LABTECH, Ortenberg, Germany).
The calibration curve was constructed by plotting the fluorescence intensity of Rh123 against the Rh123 concentration in the blank supernatant (PBS). The concentrations of standard solution ranged from 5 to 500 nM. The concentration of Rh123 in organoids was calculated according to the constructed concentration-fluorescence standard curve.
Results and Discussion
Three methods were used to prove that the 3D organoid was suitable to imitate small intestinal epithelium. Firstly, the crypts released from the small intestine were cultured as previously described [15] . They underwent multiple fission events and formed enclosed crypt-like three-dimensional structures on the fourth day ( fig. 1A) . Secondly, reverse-transcription PCR was used to assess the expression of P-gp mRNA. Mice express two genes encoding MDR1-type P-gps, including abcb1a and abcb1b [20] , while abcb1a is the major gene expressed in the intestinal epithelium [21] . As shown in fig. 1B , there was no difference in the expression of abcb1a between intestine, crypts and organoids. Thirdly, we assessed the expression of P-gp protein in both small intestine and organoids with immunohistochemistry. In the small intestines, it was shown that P-gp protein expressed on the apical surface ( fig. 1C ) and it was also detected to express on the inside surface of organoids ( fig. 1D ). These results indicated that 3D organoids kept physiological expression level of P-gp compared with the normal small intestine. Rh123 was chosen as the substrate of P-gp because it as a kind of fluorescent dye could be detected by automatic microplate reader sensitively [16, 22] . When supplemented in the medium, Rh123 can be conducted active transepithelial transport by 3D organoids in the basolateral to apical direction [16] . Good linearity (r 2 > 0.99) was obtained over the concentration and ranged from 5 to 500 nM for Rh123 in PBS ( fig. 2A ). Based on this method, the concentration of Rh123 in organoids of different groups was obtained. As shown in fig. 2B , to eliminate the difference caused by the amounts of organoids, total quantity of Rh123 was divided by the organoid numbers to gain the mean concentration. It was indicated that the concentration of Rh123 in organoids increased with the extension of incubation time. In addition, to make validation about this newly developed approach, we assessed different P-gp inhibitors, including verapamil, quinidine and mitotane (NSC-38721), on the transport of Rh123 across 3D organoids. The fluorescence intensity of Rh123 in both control and P-gp inhibitor groups at different time-points was investigated. Data showed that all verapamil, quinidine and mitotane significantly inhibited the transport of Rh123 into 3D organoids (p < 0.05, fig. 2B ), which were caused by the inhibition on P-gp. Verapamil and quinidine as the first-generation P-gp inhibitors were also reversibility inhibitors [23] , whereas mitotane was the third-generation inhibitor [24] . In this study, both quinidine and mitotane exhibited more potent inhibition on Pgp than verapamil, which was also consistent with the previous studies [23, 25] . In addition, mitotane showed the most potent inhibition on P-gp, which may be due to its high specificity binding to P-gp. Until now, caco-2 cell monolayer model has been still extensively used for drug permeability assessment by researchers around the world. However, variability of experimental results in caco-2 cell monolayer model may exist between different laboratories due to the culture condition and cell passage. In recent years, the culture of 3D organoids as a new technology has been applied for a P-gp-mediated drug transport study [16] . Compared with the caco-2 cell system, the 3D organoids are more similar to intestinal epithelium physiologically, because they are derived from single 'normal' stem cell. In addition, the shorter culture period and the simple operation should be regarded in the 3D organoid model. Mizutani et al.
[16] studied P-gp-mediated drug transport via the measurement of Rh123 with 3D organoids for the first time. Although their method is able to visualize Rh123 using the real-time imaging system, it could not be used for high-throughput drug screening because of long detection cycle. Moreover, only one organoid could be monitored at a time [16] , which would make a difference with the physical truth. In contrast, the present study firstly used ultrasonic cell disruptor to smash the organoid and then used automatic microplate reader to detect the concentration of Rh123. Thus, compared with the previous method, this newly developed approach could be used to simultaneously detect a lot of samples at every time. Moreover, to eliminate the difference caused by the amounts of organoids, total quantity of Rh123 was divided by the organoid numbers to gain the mean concentration, which could reflect the general status of the organoid. Therefore, this novel method was more rapid and efficient to measure Rh123 in the A B The concentration of Rh123 in organoids was increased with the extension of incubating time. All three different P-gp inhibitors significantly inhibited the transport of Rh123 into 3D organoids. Results were shown as mean AE S.D. *p < 0.05 and **p < 0.01 compared to control (no P-gp inhibitor) performed with one-way analysis of variance.
3D organoid for P-gp inhibitors, especially for screening in a high-throughput way. In addition, as caco-2 cell monolayer model is the most widely used for the evaluation of P-gp substrates and inhibitors, the certain guidelines according to FDA can be used, especially including some parameters, such as the efflux ratio (ER). In contrast, 3D organoids are only a newly developed model for P-gp-mediated drug transport and many factors remain uncertain. Thus, further studies should be explored, including making the certain guidelines.
In summary, a rapid, sensitive and efficient method was developed to measure Rh123 in the 3D organoid in this study. The present method could serve as a new model to study P-gp, especially screening P-gp inhibitors in a high-throughput way. 
